Journal
LIFE SCIENCES
Volume 264, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.lfs.2020.118645
Keywords
Glucagon-like peptide-1; Incretins; Diabetes mellitus; Cognition; Memory; Alzheimer's disease
Ask authors/readers for more resources
GLP-1 receptor agonists not only improve glycemic control, but also have potential benefits in improving cognitive performance through multiple molecular mechanisms, which could be particularly beneficial for diabetic patients with cognitive impairments.
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of antidiabetic drugs that improve the glycaemia via several molecular pathways. Recent evidence suggest that they also have additional effects modulating pathophysiologic pathways included in cognitive disorders. Since some forms of cognitive dysfunction such as Alzheimer's disease are more common among diabetic patients than in the normal population, antidiabetic drugs that have neuroprotective effects affording protection for cognitive disorders would be of benefit. Therefore, we reviewed the pharmacologic effects of GLP-1 analogues and found that they may have the additional benefit of improving cognitive performance via at least eight molecular mechanisms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available